Evidence map›Paper›PMID 42088218›Full record

ArticleFrontiers in oncology2026

A case report of secondary retroperitoneal lymph node tuberculosis following chemotherapy for acute myeloid leukemia with literature review.

Yizhuo Liu, Yuxia Jiang, Fenglin Shen, Mingxia He, Yunfeng Sun, Xiaofeng Xu, Huifang Jiang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yizhuo LiuTongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University (College of Integrated Traditional Chinese and Western Medicine Clinical Medicine), Hangzhou, Zhangjiang, China.
Yuxia JiangDepartment of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhangjiang, China.
Fenglin ShenDepartment of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhangjiang, China.
Mingxia HeDepartment of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhangjiang, China.
Yunfeng SunDepartment of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhangjiang, China.
Xiaofeng XuDepartment of Oncology and Hematology, Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China.
Huifang JiangDepartment of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhangjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of secondary retroperitoneal lymph node tuberculosis (TB) in patients with acute myeloid leukemia (AML) is relatively low, making it challenging to diagnose in clinical practice. This paper reports an AML patient who developed TB after chemotherapy, confirmed by positive T-SPOT results from the ultrasound-guided retroperitoneal lymph node biopsy. Eventually, the patient achieved negative conversion on T-SPOT test following individualized anti-TB treatment. This case highlights the necessity of the diagnosis of tuberculosis when infections occur in leukemia patients. Clinically, ultrasound-guided biopsy enables timely diagnosis, and favorable outcome can be attained by selecting an appropriate therapeutic regimen.

Indexed as

acute myeloid leukemiaantituberculosis therapyimmunosuppressionlymphnode punctureretroperitoneal lymph node tuberculosisT-spot test

Identifiers

PMID42088218
PMCPMC13137363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.